Can Mesoblast continue in it's current form

Mesoblast quarterly loss


Mesoblast recorded a loss of $US22.84 million for the September quarter or US3.49¢ a share, from $US24.06 million in the same period a year ago, or US4.21¢ a share. Revenue was $US3.59 million from $US1.31 million.

Cash on hand at the end of the quarter was $US115.96 million, pre-dating a $US90 million financing deal with Oaktree struck in November. The board and management believe the company can sustain the next 12 months of operations. Beyond that, Mesoblast still has $US40 million of finance available to it contingent upon reaching certain hurdles or strategic deals.

"However, whether the group can achieve its objectives for extending the cash runway beyond the 12 month period creates material uncertainty which may cast significant doubt... on our ability to continue as a going concern," the company said.